Aethlon Medical - 15 Year Stock Price History | AEMD

Historical daily share price chart and data for Aethlon Medical since 2011 adjusted for splits and dividends. The latest closing stock price for Aethlon Medical as of June 12, 2026 is 2.02.
  • The all-time high Aethlon Medical stock closing price was 340200.00 on November 24, 2014.
  • The Aethlon Medical 52-week high stock price is 27.40, which is 1256.4% above the current share price.
  • The Aethlon Medical 52-week low stock price is 1.36, which is 32.7% below the current share price.
  • The average Aethlon Medical stock price for the last 52 weeks is 5.73.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Aethlon Medical Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2026 2.2498 2.8200 3.2800 1.6506 2.0200 -27.08%
2025 21.9683 64.0000 72.4640 2.4800 2.7700 -95.97%
2024 71.1934 173.2000 174.4000 20.8000 68.8000 -60.73%
2023 266.4990 228.7200 559.9200 113.6000 175.2000 -20.48%
2022 836.8029 1568.0000 1592.0000 198.4000 220.3200 -85.19%
2021 2473.2381 2016.0000 8632.0000 1232.0000 1488.0000 -24.70%
2020 1379.4108 1000.0000 3472.0000 206.4000 1976.0000 156.49%
2019 6590.4726 18960.0000 18960.0000 668.6400 770.4000 -96.13%
2018 15442.9147 13920.0000 22800.0000 11202.0000 19920.0000 46.90%
2017 26393.4215 48216.0000 57000.0000 9612.0000 13560.0000 -73.10%
2016 64529.7544 75600.0000 92400.0000 49320.0000 50400.0000 -38.14%
2015 107650.3849 231300.0000 231300.0000 74040.0000 81480.0000 -49.23%
2014 120389.0508 108000.0000 340200.0000 61500.0000 160500.0000 57.35%
2013 73973.5718 45000.0000 159000.0000 42720.0000 102000.0000 148.54%
2012 52649.5204 36000.0000 87000.0000 30900.0000 41040.0000 27.85%
Sector Industry Market Cap Revenue
Medical Medical - Health Maintenance Organizations $0.003B $0.000B
Aethlon Medical, Inc. is a development stage medical device company focused on expanding the applications of our Hemopurifier (R) platform technology, which is designed to rapidly reduce the presence of infectious viruses and other toxins from human blood. In this regard, its core focus is the development of therapeutic devices that treat acute viral conditions, chronic viral diseases and pathogens targeted as potential biological warfare agents. The Hemopurifier(R) combines the established scientific principles of affinity chromatography and hemodialysis as a means to mimic the immune system's response of clearing viruses and toxins from the blood before cell and organ infection can occur. The Hemopurifier(R) cannot cure viral conditions but can prevent virus and toxins from infecting unaffected tissues and cells. The company has completed pre-clinical blood testing of the Hemopurifier(R) to treat HIV and Hepatitis-C, and have completed human safety trials on Hepatitis-C infected patients in India.
Stock Name Country Market Cap PE Ratio
UnitedHealth Group (UNH) United States $276.233B 18.66
Cigna Group (CI) United States $71.482B 9.09
Humana (HUM) United States $23.068B 11.22
Centene (CNC) United States $18.343B 18.19
Molina Healthcare (MOH) United States $7.599B 13.70
Select Medical Holdings (SEM) United States $2.030B 14.23
Joint (JYNT) United States $0.125B 0.00